The UK is competitive for Phase II clinical trials amongst its peer group (a sample of other countries within and outside the EU comparable to the UK), generally only trailing the US and Germany (by a small margin), according to the Clarivate Analytics Cortellis analysis. In 2016, Japan seems to benefit from a significant uptake in initiated Phase II trials, which could be linked to innovation programmes and investment in their regulatory agency, PMDA. Over this period further exploration and review over time is needed to come to any conclusions. Otherwise, every other country reviewed saw a slight decline in Phase II trial initiations in 2016.
Only commercial trials related to pharmaceutical drug development and molecular/biological entities were included. Collaborative trials were only included if one or more partners were a commercial organisation and all therapeutic areas were included in this analysis.